Enanta制药 ENTA 深 沪
已收盘 05-08 16:00:00 美东时间
15.34
+0.250
+1.66%
华盛通- 最 高15.70
- 今 开15.06
- 成交量 19.17万股
- 最 低 15.00
- 昨 收 15.09
- 总市值 4.45亿
- 52周最高 17.15
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 5.55
- 委 比 -19.29%
- 总股本 2901.93万
- 历史最高 127.77
- 量 比 0.85
- 振 幅 4.64%
- 历史最低 4.09
- 每 手 1
- 风险率 3.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enanta Pharmaceuticals To Highlight Pipeline Progress With Oral Presentation And Asthma Drug Posters
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an
05-04 19:13
Enanta Pharmaceuticals appeal oral argument set for May 11, 2026; litigation targets Pfizer over Paxlovid patent infringement
Enanta Pharmaceuticals appeal oral argument set for May 11, 2026; litigation targets Pfizer over Paxlovid patent infringement Enanta is appealing a Federal Circuit case against Pfizer seeking damages for alleged infringement of U.S. Patent No. 11,358,953 related to Paxlovid. Oral argument in the app
03-26 20:02
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference Enanta Pharmaceuticals, Inc. will participate in a management fireside chat at The Citizens Life Sciences Conference on March 10, 2026 at 10:45 a.m. ET in Miami Beach, Florida. A live webcast will be available via the “Events
03-03 20:00
Enanta Pharmaceuticals präsentiert präklinische Daten zu KIT-Inhibitor EDP-978 gegen Typ-2-Immunkrankheiten
Enanta Pharmaceuticals präsentiert präklinische Daten zu KIT-Inhibitor EDP-978 gegen Typ-2-Immunkrankheiten Enanta Pharmaceuticals Inc. hat angekündigt, präklinische Daten zu EDP-978, einem KIT-Inhibitor zur Behandlung mastzellvermittelter Typ-2-Immunerkrankungen, auf der Jahrestagung der American A
02-10 20:04
Enanta Pharmaceuticals präsentiert präklinische Daten zu EDP-978 auf der AAAAI-Jahrestagung
Enanta Pharmaceuticals präsentiert präklinische Daten zu EDP-978 auf der AAAAI-Jahrestagung Enanta Pharmaceuticals Inc. wird präklinische Daten zu EDP-978, einem KIT-Inhibitor zur Behandlung von mastzellvermittelten Typ-2-Immunerkrankungen, auf der Jahrestagung der American Academy of Allergy, Asthm
02-10 20:00
Enanta Pharmaceuticals Q1 revenue beats estimates
Enanta Pharmaceuticals Q1 revenue beats estimates Overview Biotechnology firm's fiscal Q1 revenue rose, beating analyst expectations Net loss for fiscal Q1 narrowed compared to the previous year Outlook Enanta anticipates cash resources to fund operations into fiscal 2029 Result Drivers ROYALTY REVE
02-10 05:09
Enanta Pharma Earnings Review: Q1 Summary
The earnings results for Enanta Pharma (NASDAQ:ENTA) for Q1 were made public on...
02-10 05:02
Enanta Pharma Q1 EPS $(0.42) Beats $(0.81) Estimate, Sales $18.615M Beat $16.140M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.81) by 47.96 percent. This is a 60 percent increase over losses of $(1.05) per share from the
02-10 05:01
BRIEF-Enanta Pharmaceuticals Q1 Revenue USD 18.615 Million Vs. IBES Estimate USD 16.1 Million
BRIEF-Enanta Pharmaceuticals Q1 Revenue USD 18.615 Million Vs. IBES Estimate USD 16.1 Million Feb 09 (Reuters) - Enanta Pharmaceuticals Q1 operating income USD -11.253 million. Q1 pretax profit USD -11.914 million Q1 operating expenses USD 29.868 million Q1 net income USD -11.938 million
02-10 05:01
Enanta Pharmaceuticals Inc. Q1 net loss narrows to USD 11.9 million
Enanta Pharmaceuticals Inc. Q1 net loss narrows to USD 11.9 million Enanta Pharmaceuticals Inc. reported its financial results for the first quarter ended December 31, 2025. Revenue for the period was USD 18.62 million. Research and development expenses totaled USD 20.86 million, while general and a
02-10 05:01
